


## Qiagen, Illumina accelerate NGS adoption

08 October 2019 | News

## Partnership to Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests



Illumina, Inc. and QIAGEN N.V. have announced a 15-year partnership intended to broaden the availability and use of *next-generation sequencing* NGS-based in-vitro diagnostic (IVD) kits, including companion diagnostics, for patient management.

The agreement grants QIAGEN non-exclusive rights to develop and globally commercialize IVD kits to be used together with Illumina's MiSeq<sup>™</sup> Dx and NextSeq<sup>™</sup> 550Dx Systems. The agreement also includes rights for expansion of the partnership on future Illumina diagnostic (Dx) systems. Both partners are also exploring opportunities for QIAGEN to develop and market companion diagnostics based on Illumina's TruSight Oncology (TSO) assays that enable comprehensive genomic profiling of tumor samples in immunotherapy.

Illumina and QIAGEN will cooperate to commercialize a menu of clinically validated workflows that combine QIAGEN's proprietary content and bioinformatics solutions. The partnership will initially focus on commercializing oncology IVD kits to support patient management and may expand in the future to include additional clinical diagnostic fields, such as cardiology, hereditary diseases, infectious diseases, as well as inflammatory and autoimmune diseases.